Abstract: Siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity are described. The high affinity siderocalin-metal chelator combinations include a number of chelator backbone arrangements with functional groups that coordinate with metals. The siderocalin-metal chelator combinations can be used to deliver radionuclides for imaging and therapeutic purposes.

Abstract: Provided herein are combination therapies involving administration of an immunotherapy involving a cell therapy, such as a T cell therapy, and an inhibitor of gamma secretase. Also provided are methods for engineering, preparing, and producing the cells, compositions containing the cells and/or gamma secretase inhibitor, and kits and devices containing and for using, producing and administering the cells and/or gamma secretase inhibitor, such as in accord with the provided combination therapy methods.

Abstract: A method for analyzing an ability of target nucleic acid sequences to impact gene expression is described. In an embodiment, the method includes cloning the target nucleic acid sequences and associated barcode nucleic acid sequences into a plurality of plasmids, sequencing the plasmids to provide long-read sequencing information based on a target nucleic acid sequence of the target nucleic acid sequences and an associated barcode nucleic acid sequence, associating the target nucleic acid sequence with the associated barcode nucleic acid sequence based on the long-read sequencing information, transducing the plurality of plasmids into a plurality of cells, extracting DNA, total mRNA, and polysome-bound mRNA from the cells, sequencing the barcode nucleic acid sequences in the extracted DNA, total mRNA, and polysome-bound mRNA to provide short-read sequencing information, and analyzing the target nucleic acid sequences by comparing the long-read sequencing information and the short-read sequencing information.

Abstract: SMA actuators and related methods are described. One embodiment of an actuator includes a base; a plurality of buckle arms; and at least a first shape memory alloy wire coupled with a pair of buckle arms of the plurality of buckle arms. Another embodiment of an actuator includes a base and at least one bimorph actuator including a shape memory alloy material. The bimorph actuator attached to the base.

Abstract: Provided herein are methods and compositions for overcoming resistance to and/or augmenting efficacy of Prostate specific membrane antigen (PSMA)-directed therapies in a subject. In some embodiments, the method comprises administering to the subject in need thereof an effective amount of at least one agent capable of modulating the expression of PSMA. The disclosure also is directed to a method for sensitizing a cancer to a PSMA-targeted therapeutic agent and/or a PSMA-targeted theranostic agent in a subject in need thereof. Also provided are methods and compositions for treating prostate cancer in a subject in need thereof.

Abstract: The invention relates to a structure comprising at least one thermal management element comprising: a composite body (3) containing at least one phase change material (PCM) in a structuring rigid matrix, such that the composite body is self-supporting regardless of the phase of the phase change material contained, the composite body (3) being shaped to locally externally present at least one elongated depression (11) which by itself defines a channel wall (13) suitable for the circulation of a fluid.

Abstract: Compositions and methods for treatment of conditions associated with IDH1/2 mutation(s) are disclosed. The compositions and methods include administering an SRC inhibitor and a p70 S6 kinase/AKT (S6K/AKT) inhibitor. Examples of conditions associated with IDH1/2 mutation(s) include intrahepatic cholangiocarcinoma (ICC), oligodendrogliomas, astrocytomas, glioblastomas, leukemias, adenocarcinoma, gliomas, melanomas, oligoastrocytomas, invasive breast carcinoma, invasive ductal carcinoma, and myelodysplastic syndromes.

Abstract: Methods and compositions for modulating the myeloid arm of the immune system are described. The methods and compositions modulate the myeloid arm of the immune system by stimulating or inhibiting Sema4 and/or a PlexinD1 receptor. Stimulating Sema4 and/or a PlexinD1 receptor down-regulates or dampens the myeloid arm of the immune system while inhibiting Sema4 and/or a PlexinD1 receptor up-regulates or heightens the myeloid arm of the immune system. The ability to modulate the myeloid arm of the immune system provides many advances such as reducing immune-responsiveness to various forms of stress and enhancing immune responsiveness to physiological challenges.

Abstract: A pressure/force sensor comprises a diaphragm structure including a sensing element and a lead structure extending from the diaphragm structure and including first and second traces electrically coupled to the sensing element. The diaphragm structure and the lead structure include a circuit assembly comprising a common insulating layer and a common conductor layer on the insulating layer. The conductor layer includes at least a portion of the sensing element and at least the first trace.

Abstract: Siglec-8 antibodies and uses thereof are described. The Siglec-8 antibodies can be fully human and can be used for a variety of purposes, including in the research, diagnosis, and treatment of eosinophil and mast cell related disorders, such as asthma, rhinitis, dermatitis, eosinophilic gastrointestinal disorders, eosinophilic pneumonia, anaphylaxis, urticaria, eosinophilic cellulitis and fasciitis, Churg-Strauss syndrome, hematologic malignancies involving eosinophils or mast cells, and mastocytosis.

Abstract: Anti-CD33 antibodies are described. The anti-CD33 antibodies can bind within the V-set Ig-like domain or the C2-set Ig-like domain of CD33. Epitopes on the C2-set Ig-like domain can provide a “pan-binding” site, to which the cognate antibody will bind regardless of whether the CD33 molecule also contains the V-set domain (as in, for example, CD33FL) or not (as in, for example, CD33?E2). Alternative epitopes on the C2-set Ig-like domain are accessible for binding if the V-set domain is absent (e.g., as in CD33?E2). Antibodies that bind an epitope on the C2-set Ig-like domain (whether they exhibit pan or V-set absent binding) are directed at novel therapeutic targets and can increase therapeutic efficacy against CD33-related disorders. Also described are molecules comprising a binding-competent domain from at least one described anti-CD33 antibody, including scFvs, bi-specific antibody molecules, chimeric antigen receptors, and immunoconjugates. Methods of use are also provided.

Abstract: Targeted therapeutics for the treatment of cancers expressing FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, and/or FRAS1 are described. The targeted therapeutics can include a chimeric antigen receptor (CAR) expressed by an immune cell or an antibody-targeted therapeutic. The targeted therapeutics can be used to treat a variety of cancers including solid tumors and blood cancers, such as CBFA2T3-GLIS2 acute myeloid leukemia (C/G AML).

Abstract: Provided are compositions and methods of T cell-based immunotherapies targeting hematologic malignancies that contain a mutation in the SF3BI protein.

Abstract: A neutralizing composition comprising ascorbic acid as a reducing agent, citric acid as a chelator and a pH adjusting agent applied to microetched copper substrates bussed to stainless steel, which have been cleaned with an agent comprising permanganate ions. Unlike the prior art neutralizing agents comprising oxalic acid, which leave insoluble residue on the surface of the copper substrate, the present neutralizing composition leaves no residue and acts quickly. A surprising reduction in defects of Ni—Au plated copper substrates is achieved by utilization of the neutralization composition in a manufacturing process.

Abstract: Provided herein are combination therapies involving administration of an immunotherapy involving a cell therapy, such as a T cell therapy, and an inhibitor of gamma secretase. Also provided are methods for engineering, preparing, and producing the cells, compositions containing the cells and/or gamma secretase inhibitor, and kits and devices containing and for using, producing and administering the cells and/or gamma secretase inhibitor, such as in accord with the provided combination therapy methods.

Abstract: Provided is a process for the degradation of at least one polymer of an alkene carbonate, a polymeric composition for a lithium-ion battery electrode having a degradation residue obtained by this process, a process for the preparation thereof, an electrode and a battery incorporating it and a degradation process for the sintering of ceramics. The degradation process includes a reaction at 120° C. and 270° C., and under air of a primary amine with a poly(alkene carbonate) polyol, which depolymerizes it in order to obtain a non-polymeric degradation residue. This composition includes an active material, an electrically conductive filler, a polymeric binder and a residue from the degradation under air between 120° C. and 270° C. of a sacrificial phase which includes the polymer and which has been melt blended beforehand with the active material, with the filler and with the binder in order to obtain a precursor mixture of the composition.

Abstract: The present disclosure provides methods for detecting antigen-specific cells, such as T cells or B cells, using a proximity ligation assay (PLA) in which at least one of the PLA probes is a peptide-major histocompatibility (MHC) multimer or a B cell specific antigen bound to an oligonucleotide. Also provided are kits for use in such methods.

Abstract: Embodiments include engineered minicircle-producing bacterium with differential methylation capability, as well as kits and compositions comprising the bacterium. Further described are methods of using of the bacterium for producing differentially methylated minicircle DNA, and for improving transformation efficiency of exogenous DNA in intractable bacteria.

Abstract: The invention relates to a structure comprising at least one thermal management element comprising : a composite body (3) containing at least one phase change material (PCM) in a structuring rigid matrix, so that the composite body is self-supporting regardless of the phase of the phase change material contained, and/or a plastic or metal bag, gas-tight and under partial internal vacuum, having a shape maintained by the internal vacuum, the composite body (3) and/or the bag being shaped so as locally to present externally at least one elongated cavity (11) which by itself defines a channel wall (13) suitable for the circulation of a fluid.

Abstract: A window module (60) for a vehicle, in particular automobile, comprising: a fixed window (22) comprising an internal face (22c) and an external face (22d), a movable window (14) comprising an internal face (14c) and an external face (14d), edges (14b, 22a) of the windows facing one another and defining a clearance (J) between them, and the external faces (14d, 22d) of the windows being substantially aligned, an elongated guide (26) extending along said edges and attached to the internal face (14c) of the movable window (14), an elongated upright (62) extending along said edges and attached to the internal face (22c) of the fixed window (22), and a trim element (70) fitted and attached to the upright, this trim element comprising at least one member (72) for retaining the guide in a housing (L) of the upright.